Multivariate analysis demonstrated that the risk of TTP was higher in patients who underwent unrelated BMT (P value = 0.02). Acute GVHD, stage of disease at BMT, conditioning with TBI, gender, age, did not appear to be associated with the occurrence of TTP. As to the outcome, TTP resolved in 19 patients while in nine it was the principal cause of death (32.1%). In patients with TTP, LDH peak value was the only statistically significant factor (P = 0.001) related to severe TTP. In conclusion, our experience demonstrates that leukemic children undergoing BMT, especially from an unrelated donor, should be carefully assessed for TTP which appears to be a severe and relatively common transplant-related complication when strict diagnostic criteria are applied. Bone Marrow Transplantation (2000) 26, 1005-1009.
Thrombotic thrombocytopenic purpura (TTP) related to bone marrow transplantation (BMT) is one of the problems which has emerged over the last 15 years and which was initially described as hemolytic uremic syndrome. 1, 2 Incidence of TTP ranges from 5 to 70% in allogeneic bone marrow transplantation and 3-20% in autologous BMT. [3] [4] [5] [6] [7] [8] Different diagnostic criteria for TTP and overlapping clinical events in the early post-BMT phase can explain the wide range.
TTP is related to endothelial damage and increased platelet aggregation largely caused by an increased circulation of large von Willebrand factors especially in the first 2 months after BMT, with consequent functional disorders of several organs. The concomitant presence of hemolytic anemia and thrombocytopenia in patients suffering from TTP, may also substantially increase transfusion requirements. 9 We studied the impact and course of TTP, diagnosed by parallel criteria in a multicenter study with the aim of analysing incidence, risk and prognostic factors. Given the problems with diagnosis, TTP is often under recognised and treated late which results in a particularly high mortality rate compared to other post-transplant complications.
Finally, it was not the principal aim of this retrospective study to evaluate treatment results, particularly as treatment was carried out according to each center's own protocol.
Patients and methods
Our study included 131 consecutive patients (79 males and 52 females) who underwent allogeneic BMT between 1 January 1994 and 31 December 1997 at four Italian pediatric BMT centers.
Clinical charts were reviewed and a retrospective data collection form was specifically designed for this study. Table 1 shows the characteristics of patients who did (28/131) and did not (103/131) develop TTP.
The diagnosis of TTP was evaluated on the basis of clinical and laboratory criteria, according to current knowledge of this pathology as described in the literature. [4] [5] [6] [7] [8] [9] TTP was diagnosed when patients experienced the following: (1) microangiopathic hemolysis with negative Coombs test associated with unexplained drop in hemoglobin level and platelet count, increased number of reticulocytes, evidence of red cell fragmentation with or without erythroblasts on the blood smear, increased value of indirect bilirubin (double of the normal value); (2) increased serum lactic acid dehydrogenase (LDH) activity (more than 500 UI/l). The presence of central nervous system dysfunction with or without renal impairment and/or occurrence of severe gut or bladder bleeding together with criteria 1 and 2 has been considered as severe TTP. LDH peak level was registered throughout the course of TTP. TTP index (LDH/platelets ratio) defined according to published data, 7 was assessed at TTP diagnosis, and indicated severe TTP when у20. We considered TTP to be resolved when there were no further signs of this pathology or its life-threatening outcome.
Of the 131 transplanted patients, 82 underwent 'related' BMT and 49 'unrelated' BMT, at the median age of 8.7 years (range 1-18).
One hundred and one patients were suffering from acute lymphoblastic leukemia (35 in first CR, 54 in second CR, 17 in more than second CR and 24 with active disease: for one patient remission status was unknown), 21 from acute myeloid leukemia (most of these in first CR) and nine with myelodysplastic syndrome (Table 1) according to the FAB classification. 10, 11 Average age at diagnosis of the underlying disease was 6.1 years (median 5.1 years and range 0.1-15.9).
Conditioning regimens included total body irradiation (f-TBI, 2 Gy twice a day for 3 days) combined with cyclophosphamide (30 patients) or with additional drugs (77 patients), or high-dose chemotherapy alone (21 cases); in three cases the conditioning regimen was not specified.
For graft-versus-host-disease (GVHD) prophylaxis, all but three patients received cyclosporin A (CsA) often combined with other drugs (ATG, steroids, methotrexate) at standard doses 12 in order to maintain the CsA plasma levels around 200-300 ng/ml.
Supportive care was carried out according to GITMO (Gruppo Italiano Trapianto di Midollo Osseo) and AIEOP (Associazione Italiana Emato-Oncologia Pediatrica) guidelines. 13, 14 
Statistical analysis
The association between candidate risk factors and occurrence of TTP was evaluated by comparing the patients who developed TTP with those who did not, using the chisquare test or the Fisher exact test. A logistic regression analysis 15 was then performed to simultaneously assess the effects of the following factors on TTP: gender, age at BMT, marrow remission at BMT, type of conditioning regimen, type of marrow donor, a-GVHD. Fisher's exact test and t-test were applied to assess the respective impact of TTP index and LDH peak levels on TTP-related mortality.
Results
The most relevant clinical and laboratory data concerning diagnosis, therapy and patient outcome, are listed in Table 2 . Twenty-eight of 131 transplanted patients (21.4%) developed TTP at a median time of 46 days after BMT (range 21-80), for a median duration of 47 days (range 2-216).
Twelve out of the 28 patients (42.9%) had undergone 'related' BMT at a median age of 9.5 years (range 2.5-18.4), while 16/28 (57.1%) had undergone 'unrelated' BMT (median age 10.8, range 3.0-15.5). Twenty-one percent of children who developed TTP were in first complete remission, 35.7% in second CR, 28.6% in more than second CR and 14.3% had active original disease.
The multivariate analysis in all series (Table 3) showed that the risk of TTP was significantly higher for unrelated BMT patients, compared to the others (relative risk 2.9; P value 0.02).
TTP was mild and resolved in 19/28 patients although 3/19 died from other non-TTP-related causes. In the remaining 9/28 children, the course of TTP was particularly severe and constituted the main cause of death (32.1%). This latter group all developed serious nephropathy, with average maximum creatinine value of 1.9 mg/dl (range 1-2.5), hypertension and neuropathy as a final complication. The majority of these patients (4/9) also developed severe hemorrhagic cystitis, enteritis and pancreatitis which resulted in an increased need for blood products and support treatment.
Comparing the group of patients who survived after TTP with those who did not, we found that the peak LDH values throughout the course of TTP were significantly related to outcome (P value = 0.001) while TTP index did not seem to play a significant role in TTP evolution.
Therapeutic approach was not homogenous, largely due to relatively late diagnosis of TTP in the majority of patients. Two patients (Nos 20 and 22, who died from multiorgan failure, were only recognised as suffering from severe TTP on the basis of this survey and therefore had not been treated.
Only five children were given standard treatment An estimated relative risk (RR) of 1 indicates no difference, while RR Ͼ1 (Ͻ1) that one group has a higher (lower) risk with respect to the reference group (indicated with a dash).
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(plasma, plasmapheresis) combined with defibrotide given at an average dose of 14.2 mg/kg/day with a median duration of 23 days (range 1-37) while the remaining patients followed different treatment combinations ( Table 2) . Regardless of the type of treatment, therapy started on average 13 days after TTP diagnosis (median 4, range 0-65 days) and lasted for about 34 days (median 32, range ). An average of three plasmaphereses per week (minimum = 1, maximum = 4) were carried out. Thirteen out of 28 patients received plasma. The median duration of therapy with plasma was 13 days (range 4-62) and the average number of plasma units infused per patient per week was also 13 (median 10, range .
Discussion
This study retrospectively assessed 131 consecutive leukemic patients transplanted in four pediatric centers to evaluate the impact of TTP. The study adopted homogeneous diagnostic criteria with the principal aim of evaluating the incidence of TTP and limiting any bias.
The fact that 21% of our patients suffered from TTP deserves some comment. The incidence of this transplantrelated complication is about average, compared to the wide ranging incidence described in previous reports, [16] [17] [18] [19] [20] [21] [22] which may be due to discordant diagnostic criteria as well as to different experiences regarding the course of TTP. In fact, in the majority of patients with TTP, some superimposed negative events such as GVHD, renal dysfunction, infection and severe hemorrhagic patterns often make it difficult to consider TTP as an emerging primary complication.
Furthermore, we tried to define which risk factors could determine the occurrence of TTP, taking into consideration that the real etiology of BMT-associated TTP, is as yet unknown. Our study showed that patients who underwent 'unrelated' BMT were most at risk of developing TTP (P = 0.02).
One may speculate that the more damage there is to the endothelium, the higher the incidence of TTP which may just occur in unrelated BMT patients because of not only the increased levels of inflammatory cytokines early after BMT but also because of increased activation of donor T cells. 23, 24 In our experience gender, age at BMT, marrow status at BMT, conditioning regimen (with or without TBI) and GVHD did not seem to have an impact on incidence of TTP. This is probably due to the relatively small number of patients in our study but we should not rule out the possibility that different combinations of the above-mentioned factors could favour the occurrence of TTP. Endothelial damage in this setting is a crucial triggering factor, supported by the presence of high levels of thrombomodulin, P-selectin, plasminogen activator inhibitor (PAI-1) which, in the presence of unusually large von Willebrand factors, can contribute to an increased quantity of hyaline thrombi, mostly due to aggregated platelets. [25] [26] [27] Some of these coagulation disorders have been demonstrated, especially in unrelated BMT. 28 The current study also found a correlation between elevated LDH peak values during the course of TTP and a worse prognosis of TTP (P = 0.001). Surprisingly, neither a high TTP index at TTP diagnosis nor an earlier onset, seemed to correlate with a worse prognosis.
Analysing TTP outcome in our series, we emphasize that any delays in diagnosing TTP could have decreased treatment efficacy. Furthermore, the retrospective nature of our study did not allow assessment of the value of the different treatments adopted, given that plasma or plasma exchanges were not always timely or continuously performed, owing to management difficulties in some single centers. Bearing this in mind, a better, ongoing relationship between hematooncology teams and the blood transfusion services should be established, for optimal management of patients with TTP.
A consensus should be obtained on the use of plasma exchange, which has recently been proved to be more effective than plasma infusion, 29, 30 as it is capable of eliminating the large von Willebrand factors forms or some endogenous endonucleases which can induce apoptosis of the damaged endothelial cells.
Mortality rate attributable to thrombotic microangiopathy is highly variable in the literature, ranging from 0 to 73% in autologous bone marrow recipients and from 4 to 100% in allogeneic bone marrow recipients dying of TTP-related causes.
3,7,16-18,31-34 Infectious diseases, mostly fungemia, uncontrollable a-GVHD, severe renal dysfunction and central nervous system involvement are often the final causes of death. The high rate (32.1%) of TTP-related mortality in our series is noteworthy, albeit expected, given that the majority of our deceased patients had severe TTP. Furthermore, the high percentage of unrelated BMTs in our study (42.9%) could have been a risk factor per se, for transplantrelated mortality.
With regard to the treatment of TTP in BMT patients, there are a few promising reports regarding the use of defibrotide, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] which seems to have a considerable antithrombotic effect due to its profibrinolytic activity, 36, 37 based on its ability to induce release of plasminogen activator factor from the vascular tissue 38 and to decrease blood concentration of plasminogen activator inhibitor. 39 These and other defibrotide-related effects, the most important of which concerns inhibition of platelet aggregation, have recently been acknowledged to be of benefit in post-BMT venoocclusive disease, 40 which, like TTP, can occur as a result of endothelial damage.
Given the antithrombotic effect of defibrotide and its low toxicity, it is reasonable to hypothesize a role for this drug in TTP treatment protocols, which already include plasma exchange, possibly in the context of multicenter prospective clinical trials, with the aim of reducing transplant-related mortality.
In conclusion, our study suggests the opportunity for earlier diagnosis, more careful clinical monitoring and the need for future studies on TTP, which appears to be a frequent and often life-threatening post-transplant complication.
